211 related articles for article (PubMed ID: 18580862)
1. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
2. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
3. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Kurtz TW
Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.
Jugdutt BI
Clin Interv Aging; 2010 Dec; 5():403-16. PubMed ID: 21152242
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
6. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan: just an antihypertensive agent? A literature review.
Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
[TBL] [Abstract][Full Text] [Related]
9. A perspective on telmisartan and cardiovascular risk.
Giles TD
Rev Cardiovasc Med; 2007; 8(3):154-9. PubMed ID: 17938615
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
11. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
[TBL] [Abstract][Full Text] [Related]
15. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
[TBL] [Abstract][Full Text] [Related]
17. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular protection: a breakthrough for high-risk patients?
Ferrari R
J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
Cao Z; Cooper ME
Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
[TBL] [Abstract][Full Text] [Related]
20. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Zimmermann M; Unger T
Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
